Oncology Institute, Inc. (TOI) has disclosed a new risk, in the Accounting & Financial Operations category.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
The Oncology Institute, Inc. faces a significant business risk if it must record further goodwill impairment charges. The company’s financials have already been impacted by a $16,867 impairment due to a diminished fair value of its reporting unit, influenced by declining stock prices and adverse macroeconomic and industry conditions. Future assessments, driven by persistent or worsening factors, could mandate additional impairments, potentially affecting the entire balance of remaining goodwill and jeopardizing the company’s adherence to financial covenants within its Facility Agreement. Such developments could substantially deteriorate Oncology Institute’s financial health and operating results.
Overall, Wall Street has a Moderate Buy consensus rating on TOI stock based on 1 Buy.
To learn more about Oncology Institute, Inc.’s risk factors, click here.
